125572-92-1

Basic information

• Product Name: Rotigotine hydrochloride
• Synonyms: (R)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol hydrochloride;N 0924 hydrochloride
• CAS NO: 125572-92-1
• Molecular Formula: C19H25NOS.ClH
• Molecular Weight: 351.939
• Mol File: 125572-92-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Rotigotine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Rotigotine hydrochloride(125572-92-1)
• EPA Substance Registry System: Rotigotine hydrochloride(125572-92-1)

Safety Data

• Hazardous Substances Data: 125572-92-1(Hazardous Substances Data)

Usage

General Description

Rotigotine hydrochloride is a dopamine agonist that acts on dopamine receptors in the brain. It is primarily used for the treatment of Parkinson's disease and restless legs syndrome. The drug is available as a transdermal patch for continuous delivery of the medication. Rotigotine hydrochloride works by mimicking the effects of dopamine in the brain, helping to reduce symptoms such as tremors, stiffness, and difficulty with movement in Parkinson's disease, and relieving discomfort and urge to move in restless legs syndrome. It is important to follow the dosing instructions carefully and to be aware of potential side effects, such as nausea, dizziness, and skin irritation at the patch site.

Upstream product

• 99755-59-6 rotigotine 
• 112835-48-0 (-)-2-(N-propyl-N-2-thienylethylamino)5-hydroxytetralin 
• 39098-97-0 2-thienylacetic acid chloride 
• 32940-15-1 5-methoxy-2-tetralone 
• 1918-77-0 Thiophene-2-acetic acid 
• 165950-84-5 (S)-1,2,3,4-tetrahydro-5-hydroxy-N-propyl-naphthalen-2-ammonium hydrobromide 
• 3904-24-3 (5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 101403-25-2 (R)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-amine 
• 1352917-68-0 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-methoxy-2-phenylacetate 
• 93601-86-6 (S)-(-)-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 1352917-67-9 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-hydroxy-3-phenylpropionate 
• 1352917-66-8 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-(2-chlorophenyl)-2-hydroxyacetate 
• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 5402-55-1 2-thiophenethanol 

Relevant articles and documents

Novel Process for Preparation of Rotigotine and Intermediates Thereof

The present invention relates to a novel process for the preparation of Rotigotine of formula (I) and intermediates thereof.

IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM II OF ROTIGOTINE

The present invention relates to an improved, environment friendly and cost effective process for the preparation of crystalline Form II of Rotigotine. Rotigotine, i.e. (6S)-6-{propyl[2-(2-thienyl) ethyl]amino}-5,6,7,8-tetrahydro-l-naphthalenol represented by structural formula (I), is used for the treatment of Parkinson's disease and Willis-Ekbom disease.

S-5-SUBSTITUENT-N-2'-(THIOPHENE-2-YL)ETHYL-TETRALIN-2-AMINE OR CHIRAL ACID SALTS THEREOF AND USE FOR PREPARING ROTIGOTINE

The chiral compound S-5-substituted-N-2-(thienyl-2-yl-)ethyl-tetralin-2-amine or its chiral acid salts and preparation method thereof are disclosed, and the method for preparing Rotigotine by using the chiral compound is also disclosed. Racemic 5-substituted-N-2'-(thien-2-yl-)ethyl-tetralin-2-amine (compound 1) is resolved by using a conventional chiral acid to obtain an optically pure chiral acid salt of S-5-substituted-N,2'-(thien-2-yl-)ethyl-tetralin-2-amine, which is then dissociated to obtain S-5-substituted-N-2'-(thien-2-yl-)ethyl-tetralin-2-amine (compound 2). The compound 2 or chiral acid salt thereof is alkylated and deprotected to produce rotigotine (compound 5).